A Pilot Study of Pembrolizumab in Combination With Y90 Radioembolization in Subjects With Poor Prognosis Hepatocellular Carcinoma

CONCLUSION: In patients with localized, poor prognosis HCC, pembrolizumab in addition to glass Y90 radioembolization demonstrated promising efficacy and safety consistent with prior observations (ClinicalTrials.gov Identifier: NCT03099564; IRB Approved: 16-3255 approved July 12, 2016).PMID:38325328 | DOI:10.1093/oncolo/oyad331

Source: The Oncologist - February 7, 2024 Category: Cancer & Oncology Authors: Shawn Yu Menggang Yu Barry Keane David M Mauro Paul R Helft William P Harris Hanna K Sanoff Matthew S Johnson Bert O'Neil Autumn Jackson McRee Ashwin Somasundaram Source Type: research